Advising Crescent Biopharma, Inc. on its merger with GlycoMimetics Inc. and $200 million private placement

Our Cayman Islands Corporate team acted as Cayman counsel to Crescent Biopharma, Inc. on its merger with GlycoMimetics Inc., US$200 million private placement and subsequent redomestication from Delaware to the Cayman Islands and the combined company's listing on Nasdaq.

The combined entity, trading under the name Crescent Biopharma, Inc., commenced trading on Nasdaq on 16 June 2025 under the ticker symbol “CBIO”.

Crescent Biopharma, Inc. is a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients.

The Walkers team was led by partner Andrew Barker together with senior counsel Sam Francis and associate Miriam El Ofir. Gibson Dunn & Crutcher LLP acted as US counsel to Crescent Biopharma.